Elsevier

Clinical Therapeutics

Volume 29, Issue 8, August 2007, Pages 1579-1590
Clinical Therapeutics

Efficacy and Safety of Inhaled Zanamivir in the Prevention of Influenza in Community-Dwelling, High-Risk Adult and Adolescent Subjects: A 28-day, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

https://doi.org/10.1016/j.clinthera.2007.08.023Get rights and content

Abstract

Background: Influenza can cause significant morbidity and mortality in subjects at high risk for complications, including the elderly (age ≥65 years) and those with chronic respiratory, cardiovascular, or metabolic conditions. Effective prophylaxis can significantly reduce the disease burden in this population. Previous studies conducted primarily in non-high-risk subjects have reported the efficacy of inhaled zanamivir in preventing influenza.

Objective: This study investigated the efficacy and safety of zanamivir in preventing influenza in community-dwelling adult and adolescent subjects at high risk for complications of influenza.

Methods: This was a multicenter, randomized, double-blind, placebo-controlled, parallel-group study in community-dwelling subjects aged ≥12 years who were at high risk for developing complications of influenza, were able to use the Diskhaler device (Glaxo Group Limited, Research Triangle Park, North Carolina), and were able to take the first dose of study medication within 5 days of laboratory-confirmed local influenza activity. Eligible subjects were randomized to receive inhaled zanamivir 10 mg or placebo once daily for 28 days. The primary end point was the proportion of randomized subjects who developed symptomatic influenza during prophylaxis, as confirmed by culture and/or serology. All adverse events (AEs) occurring after the first dose of study medication were recorded.

Results: The study enrolled 3363 subjects, of whom 58% were female and 93% were white; the mean age of participants was 60.4 years (range, 12-94 years), and 4% were adolescents. Significantly fewer zanamivirtreated subjects developed symptomatic, laboratory- confirmed influenza during prophylaxis compared with placebo recipients (4/1678 vs 23/1685, respectively), representing a relative risk (RR) of 0.17 (95% CI, 0.07-0.44; P < 0.001) and a protective efficacy of 83%. The incidence of complications was reduced in zanamivir-treated subjects compared with placebo recipients (1/1678 and 8/1685), representing an RR of 0.12 (95% CI, 0.02-0.73; P = 0.042) and a protective efficacy of 88%. The numbers of zanamivir recipients (151/1678 [9%]) and placebo recipients (169/1685 [ 10 % ] ) who developed symptomatic influenza-like illness regardless of laboratory confirmation did not differ significantly (RR = 0.86; 95% CI, 0.70-1.06), indicating that zanamivir was not effective in preventing influenza-like illness that was not caused by influenza infection. Similarly, there was no significant difference in the numbers of zanamivir and placebo recipients who developed laboratory-confirmed infection regardless of symptoms (39/1678 [2%] and 52/1685 [3%], respectively; RR = 0.76; 95% CI, 0.50-1.15). Of these, 64 subjects (35 and 29) were asymptomatic; seroconversion occurred in all but 1 subject, indicating that zanamivir prophylaxis did not prevent asymptomatic seroconversion. During prophylaxis, 51% of subjects in both treatment groups reported at least 1 AE. There were no major differences in the frequency or nature of AEs between groups. The most commonly reported AEs (≥3% of subjects in each treatment group) were consistent with upper respiratory viral infection (headache: 17% zanamivir, 18% placebo; cough: 14% and 15%, respectively; throat and tonsil discomfort/pain: 13% and 14%). There were no differences between groups in the overall incidence of viral respiratory infections (5% in both groups) or ear, nose, and throat infections (2% in both groups). None of the analyzed isolates from confirmed cases of influenza exhibited reduced susceptibility to zanamivir or genotypic evidence of resistance.

Conclusions: Zanamivir, administered once daily for 28 days, was efficacious in preventing infection with the predominant circulating strains in the 2000- 2001 influenza season in the Northern Hemisphere (influenza A/New Calendonia/20/99-1ike and influenza B/ Sichuan/379/99-1ike) in these high-risk community- dwelling subjects aged ≥12 years. Zanamivir was well tolerated, with a safety profile comparable to that of placebo. No emergence of resistant virus was detected. (Clin Ther. 2007;29:1579-1590) Copyright © 2007 Excerpta Medica, Inc.

References (47)

  • JM Woods et al.

    4-Guanidino-2,4- dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor of both the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro

    Antimicrob Agents Chemother

    (1993)
  • GJ Hart et al.

    2,3-Didehydro-2,4-dideoxy-4- guanidino-N-acetyI-D neuraminic acid (4-guanidino- NeuSAc2en) is a slow-binding inhibitor of sialidase from both influenza A virus and influenza B virus

    Biochem Mol Biol Int

    (1995)
  • J McKimm-Breschkin et al.

    Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir

    Antimicrob Agents Chemother

    (2003)
  • IA Leneva et al.

    Efficacy of zanamivir against avian influenza A viruses that possess genes encoding HSN1 internal proteins and are pathogenic in mammals

    Antimicrob Agents Chemother

    (2001)
  • A Moscona

    Neuraminidase inhibitors for influenza

    N Engl J Med

    (2005)
  • AS Manta et al.

    Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: Pooled efficacy analysis

    J Antimicrob Chemother

    (1999)
  • Randomized trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections [published corrections appear in Lancet. 1999;353:504 and Lancet. 1999;353: 1104]

    Lancet

    (1999)
  • JA Hedrick et al.

    Zanamivir For treatment of symptomatic influenza A and B infection in children five to twelve years of age: A randomized controlled trial

    J Pediatr Infect Dis

    (2000)
  • FG Hayden et al.

    Inhaled zanamivir for the prevention of influenza in families

    N Engl J Med.

    (2000)
  • AS Monto et al.

    Zanamivir prophylaxis: An effective strategy for the prevention of influenza types A and B within households

    J Infect Dis

    (2002)
  • AS Monto et al.

    Zanamivir in the prevention of influenza among healthy adults: A randomized controlled trial

    JAMA

    (1999)
  • World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects

  • ML Landry et al.

    Primaryisolation of viruses

  • Cited by (45)

    • Inhaled anti-infective chemotherapy for respiratory tract infections: Successes, challenges and the road ahead

      2015, Advanced Drug Delivery Reviews
      Citation Excerpt :

      Treatment should be initiated as soon as possible following symptom onset, ideally within 48 h [178,183]. Clinical trials have shown that adherence to these treatment windows significantly reduces the duration of illness, symptom severity and the rate of influenza associated complications [181,183–186]. In a comparative study, it was shown that treatment with inhaled zanamivir was more effective than oral oseltamivir in reducing symptom severity in patients infected with either influenza A or B viruses [187].

    • Management of influenza infection in solid-organ transplant recipients:consensus statement of the group for the study of infection in transplantrecipients (GESITRA) of the spanish society of infectious diseases and clinicalmicrobiology (SEIMC) and the spanish network for research in infectiousdiseases (REIPI)

      2013, Enfermedades Infecciosas y Microbiologia Clinica
      Citation Excerpt :

      Preexposure chemoprophylaxis has been studied in the community in groups of healthy adults and patients living in institutional centers who received antiviral medications during influenza virus season. The efficacy of zanamivir and oseltamivir in preventing febrile, laboratory-confirmed influenza illness was 84% and 82%, respectively.27,35,36 Preexposure chemoprophylaxis must be administered only for the duration of the exposure.

    • Neuraminidase inhibition improves endothelial function in diabetic mice

      2023, American Journal of Physiology - Endocrinology and Metabolism
    View all citing articles on Scopus
    View full text